ERBB2 and bile duct carcinoma: Among the bile duct carcinoma patients who performed next-generation sequencing (NGS) testing, 5.4% report gene alterations involving HER2, of which 2.4% amplifications, 2.3% ERBB2 mutations, and 0.4% with mutations and amplifications present simultaneously [9].